ArticleOncology and therapy2024

Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma.

Ella Xiaoyan Du et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.